• R/R B-NHL• No prior allogeneic HSCT• min. of ≥ 2 PLoT• Prior CD19 autologous CAR-T eligible• Median age: 62 (49-79)• Stage IV disease: 66.7%• LDH>ULN: 50%• Median PLoT: 3 (1-7)• Primary refractory disease: 58%. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.